Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis

Published:2019-10-22 Issue:11 Volume:98 Page:2523-2531
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Qin Yao,Kuang Pu,Zeng Qiang,Wu Yuling,Liu Ting

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-019-03811-x.pdf

Reference37 articles.

1. Kennedy JA, Ebert BL (2017) Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol 35(9):968–974. https://doi.org/10.1200/jco.2016.71.0806

2. Kim TK, Gore SD, Zeidan AM (2015) Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol 52(3):172–183. https://doi.org/10.1053/j.seminhematol.2015.04.003

3. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P, Gratwohl A, Runde V, Niederwieser D, van Biezen A, Devergie A, Cornelissen J, Jouet JP, Arnold R, Apperley J (2000) Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110(3):620–630. https://doi.org/10.1046/j.1365-2141.2000.02200.x

4. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ (2006) Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20(1):128–135. https://doi.org/10.1038/sj.leu.2404010

5. Kindwall-Keller T, Isola LM (2009) The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 43(8):597–609. https://doi.org/10.1038/bmt.2009.28

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee;Blood;2024-05-30

2. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape;Current Oncology;2024-04-03

3. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation;Annals of Hematology;2024-02-06

4. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study;Annals of Hematology;2023-11-06

5. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms;Blood Advances;2023-07-17